title: Dabigatran: patient management in specific clinical settings.
abstract: Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has a favourable benefit-risk profile, it is being increasingly used. Dabigatran differs from vitamin K antagonists as regards its pharmacological characteristics and its impact on certain laboratory tests, and also in the lack of a direct antagonist that can reverse dabigatran-induced anticoagulation. In emergency settings such as acute bleeding, emergency surgery, acute coronary syndrome, thrombolysis for ischaemic stroke or overdosing, specific strategies are required. A working group of experts from various disciplines has developed strategies for the management of dabigatran-treated patients in emergency settings.
authors.affiliation: Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria, paul.kyrle@meduniwien.ac.at.
authors.forename: Paul Alexander
authors.initials: PA
authors.lastname: Kyrle
authors.forename: Konrad
authors.initials: K
authors.lastname: Binder
authors.forename: Sabine
authors.initials: S
authors.lastname: Eichinger
authors.forename: Reinhold
authors.initials: R
authors.lastname: Függer
authors.forename: Bernd
authors.initials: B
authors.lastname: Gollackner
authors.forename: J Michael
authors.initials: JM
authors.lastname: Hiesmayr
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
authors.forename: Wielfried
authors.initials: W
authors.lastname: Lang
authors.forename: Peter
authors.initials: P
authors.lastname: Perger
authors.forename: Peter
authors.initials: P
authors.lastname: Quehenberger
authors.forename: Franz X
authors.initials: FX
authors.lastname: Roithinger
authors.forename: Sabine
authors.initials: S
authors.lastname: Schmaldienst
authors.forename: Ansgar
authors.initials: A
authors.lastname: Weltermann
authors.forename: Hans
authors.initials: H
authors.lastname: Domanovits
mesh_terms: D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects; D019643:Arthroplasty, Replacement / Q000009:adverse effects* / Q000592:standards; D001317:Austria; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects* / Q000592:standards; D000069604:Dabigatran; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D017410:Practice Guidelines as Topic; D054556:Venous Thromboembolism / Q000209:etiology* / Q000517:prevention & control*; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000592:standards
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran